CFO of Array BioPharma Inc. (ARRY) Michael Carruthers sells 1,272 shares of ARRY on 01/12/2011 at an average price of $3.2 a share.

Array Biopharma has a market cap of $175.2 million; its shares were traded at around $3.17 with and P/S ratio of 3.2. Array Biopharma had an annual average earning growth of 20.9% over the past 10 years.

ARRY is in the portfolios of Columbia Wanger of Columbia Wanger Asset Management, Jim Simons of Renaissance Technologies LLC, Steven Cohen of SAC Capital Advisors.

CFO Recent Trades:

• Sell: CFO Michael Carruthers sold 1,256 shares of ARRY stock on 12/10/2010 at the average price of 3.24. Michael Carruthers owns at least 89,650 shares after this. The price of the stock has decreased by 2.16% since.


• Sell: CFO Michael Carruthers sold 1,220 shares of ARRY stock on 11/12/2010 at the average price of 3.33. Michael Carruthers owns at least 90,906 shares after this. The price of the stock has decreased by 4.8% since.


• Sell: CFO Michael Carruthers sold 1,225 shares of ARRY stock on 10/12/2010 at the average price of 3.32. Michael Carruthers owns at least 92,126 shares after this. The price of the stock has decreased by 4.52% since.


• Sell: CFO Michael Carruthers sold 1,415 shares of ARRY stock on 09/14/2010 at the average price of 2.88. Michael Carruthers owns at least 70,353 shares after this. The price of the stock has increased by 10.07% since.


• Sell: CFO Michael Carruthers sold 17 shares of ARRY stock on 08/23/2010 at the average price of 2.79. Michael Carruthers owns at least 71,768 shares after this. The price of the stock has increased by 13.62% since.

This is the insider trade history vs. stock price of ARRY. For the complete insider trading history of ARRY, click here.

Directors and Officers Recent Trades:

• Sell: VP, General Counsel John R Moore sold 2,959 shares of ARRY stock on 01/11/2011 at the average price of 3.3. John R Moore owns at least 356 shares after this. The price of the stock has decreased by 3.94% since.


• Sell: VP, General Counsel John R Moore sold 24,039 shares of ARRY stock on 01/06/2011 at the average price of 3.25. John R Moore owns at least 3,315 shares after this. The price of the stock has decreased by 2.46% since.


• Sell: Director Kyle Lefkoff sold 10,000 shares of ARRY stock on 11/18/2010 at the average price of 3.27. Kyle Lefkoff owns at least 44,585 shares after this. The price of the stock has decreased by 3.06% since.


• Sell: VP, General Counsel John R Moore sold 20,067 shares of ARRY stock on 10/05/2010 at the average price of 3.29. John R Moore owns at least 27,354 shares after this. The price of the stock has decreased by 3.65% since.


• Sell: VP, General Counsel John R Moore sold 6,319 shares of ARRY stock on 08/03/2010 at the average price of 3.25. John R Moore owns at least 21,317 shares after this. The price of the stock has decreased by 2.46% since.

Why CEOs Are Buying Stocks Of Their Own Companies?

1. As legendary investor Peter Lynch said: "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."
2. TOP EXECUTIVES like CEOs and CFOs are savvy buyers of their companies' shares. One long-term study showed that they beat the market on average by six percentage points a year.
3. Another study found that the aggregated activities of insiders can serve as a good indicator to locate market bottoms. Insiders as a whole are smart investors of their own companies.

Click it to Check Out What the CEO Are Trading

More Gurufocus Links

Latest Guru Picks	Value Strategies
Warren Buffett Portfolio	Ben Graham Net-Net
Real Time Picks	Buffett-Munger Screener
Aggregated Portfolio	Undervalued Predictable
ETFs, Options	Low P/S Companies
Insider Trends	10-Year Financials
52-Week Lows	Interactive Charts
Model Portfolios	DCF Calculator
RSS Feed	Monthly Newsletters
The All-In-One Screener	Portfolio Tracking Tool